A study focused on magic mushrooms in Canada revealed that nearly 80% of participants support the use of psilocybin as a medical treatment for patients experiencing distress. Moreover, approximately two-thirds of the Canadian participants from the same study concurred that psilocybin should be legally obtainable for those who require it.
Beyond just availability, a significant 84.8 percent of participants believe that the public health system should cover the costs of such therapies. Psilocybin is regarded as a viable treatment option by a majority of Canadians, especially for alleviating end-of-life distress.
[toc]
Key Takeaways:
- Residents of Québec, Ontario, Alberta, and British Columbia view psilocybin as a legitimate medical solution for managing end-of-life existential distress.
- Magic mushrooms are deemed safe for the treatment of existential distress.
- Participants in two separate double-blind trials reported immediate and lasting benefits, with effects enduring six months or more.
Understanding Existential Distress
Existential distress, closely related to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. This distress can lead to feelings of helplessness, isolation, anxiety, and a loss of meaning and purpose, particularly affecting patients with life-threatening illnesses, and can potentially induce a desire for hastened death or thoughts of suicide.
Generally, individuals facing terminal illnesses or significant life changes are the most likely to experience this form of distress. It significantly impacts their mental health and overall quality of life.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. This therapy may necessitate several sessions and may not be effective for all individuals.
The ambiguity surrounding the effectiveness of such therapy is a key reason why many individuals seek out alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Alternative
Over the last two decades, preliminary clinical studies have highlighted the potential advantages of psychedelic substances in addressing complex mental disorders. Specifically, psilocybin has demonstrated a quick and lasting reduction of existential anguish in patients approaching life’s end.
Recognizing the proposed efficacy of these hallucinogenic mushrooms, especially when conventional treatments are unsuccessful, Health Canada revised the Special Access Program in 2022. This modification permits healthcare practitioners to seek controlled substances for their patients.
Canadians’ Advocacy for Psilocybin Accessibility
An article in the Palliative Care Journal investigates societal viewpoints on psilocybin-assisted treatment for end-of-life care. The survey data comprises:
| Study Design | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of whom had former experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Conclusions | 79.3% view psilocybin-assisted therapy as a legitimate medical choice for handling end-of-life existential distress. 63.3% opine psilocybin should be integrated into medical care. 84.8% endorse the public health system offering this therapy. 44.2% believe healthcare professionals should dispense the substance without Health Canada’s supervision. |
These findings align with survey results from Canada, England, and Australia. The investigators underscored the uniqueness of their research, focusing on the utilization of psychoactive substances to mitigate existential distress in end-of-life situations.
Rationale for Canadian Advocacy of Psilocybin Usage
Increasingly, Canadians are welcoming the application of psilocybin for therapy, primarily driven by insights from esteemed research bodies. Another influential aspect is the perceived safety of psilocybin mushrooms for easing existential distress. Participants across multiple studies have not reported substantial negative health consequences, such as multi-organ failure.
| Research | Method | Results |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and sustained The therapy’s effectiveness is largely due to mystical experiences that bring about a sense of interconnectedness and deep emotional insights. These can have lasting benefits, potentially for up to six months or beyond. |
| Trial at New York University | A total of 29 patients were randomly allocated either psilocybin or the active placebo, niacin. | The results of this study were in line with those of the Johns Hopkins study, with participants who received psilocybin reporting psychological relief along with an enhanced perspective on life and death. |
| BMC Palliative Care | For this study, nineteen participants including 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist were interviewed. The objective was to understand the perception of palliative care professionals towards existential distress and their view on psychedelic therapy as a potential treatment. | Palliative care practitioners suggested that psychedelic-assisted therapy (PAT) may have potential in alleviating existential distress. |
Patient Experiences
Scientific research is not the only evidence that supports the effectiveness of psilocybin. Several narratives from patients also emphasize its potential to enhance mental wellbeing and overall quality of life.
The Journey of Yokoi
Mio Yokoi, who was battling terminal stage 4 pancreatic cancer, shares her enlightening experience during her assisted therapy. She visualizes herself on a raft, surrounded by nature and playful creatures. This vision imparts to her a profound understanding of the interconnectedness of the universe, bringing her immense peace and affirmation.
Despite accessing traditional mental health support, Yokoi experienced significant anxiety and distress following her diagnosis. Psilocybin therapy helped her reconnect with her body and provided a tangible sense of love and support, significantly improving her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare at the time of the study and identified herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy noticed significant reductions in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked about any changes in her religious or spiritual beliefs following her therapy session, she stated that these experiences had brought depth and authenticity to her beliefs.
The Experience of Brenda
In the course of her therapeutic sessions, Brenda underwent the sensation of death twice. This experience led her to perceive death not as a fear, but rather as a natural component of life’s cycle. She recognized the study as the catalyst for her recuperative journey from her childhood trauma. This profound transformation was reflected in her data, with a notable reduction in her anxiety and death-related fear, coupled with an elevated sense of spirituality.
Availability of Psilocybin Products in Canada
At present, access to psilocybin capsules and other similar products designed for managing existential distress or other mental health conditions may be limited. However, reliable online dispensaries can be an effective source of these products as needed.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Source | Originates from Brazil and some surrounding South American countries. | Discovered in Cambodia, around the Angkor Wat Temple. | Related to the Penis Envy mushrooms, which became popular in the 1970s. |
| Strength | Moderately potent; suitable for beginners. | Also moderately potent; ideal for newcomers. | Highly potent; recommended for those with a moderate to high level of experience. |
| Effects | Produces a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Triggers an energizing and enduring high, minor visual changes, enhanced creativity, euphoria, a smooth physical high, fractal images, and feelings of joy. | Induces profound shamanic experiences, vision quests, intense mystical experiences, increased creativity, focus, social awareness, and mood enhancement. |
Mitigating End-of-life Discomfort with Psilocybin Products
Existential or end-of-life distress can exert a substantial burden on many patients nearing the end of their life. Conventional treatments can sometimes be inadequate, resulting in growing support in Canada for the easier availability of magic mushrooms within the public healthcare system. This escalating public interest could We advocate for regulatory authorities to acknowledge the potential of magic mushrooms as a feasible therapeutic option. Acquire your psychedelics and mushroom delivery from Magic Mushrooms Hamilton Canada.
Frequently Asked Questions
What should patients expect during Psilocybin-Assisted Therapy?
Experiences with Psychedelic-assisted therapy (PAT) differ greatly among patients, making careful preparation and adherence to specific guidelines critical for a positive outcome. It’s crucial for patients to undergo extensive screening and mental readiness before taking the substance.
- Preparation before the Session: Patients are subjected to a detailed assessment. The therapist discusses the patient’s goals and expectations to set intentions for the session. The therapist then informs the patient about the potential effects of the process and what to expect during the session.
- The Session: During the session, patients are given a controlled dosage of the substance in a serene, distraction-free environment to promote relaxation and introspection. The therapist offers ongoing support and guidance throughout this process.
- Post-Session Integration Therapy: This therapy helps the patient interpret and assimilate their experiences. Follow-up sessions provide continuous support and counselling to reinforce the insights and changes achieved during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin engages with the brain by binding to serotonin receptors, principally the 5-HT2A receptor. This interaction can cause alterations in perception, mood, and cognition, leading to significant changes in consciousness, emotional insights, and novel viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t appropriate for all people. Patients with specific mental health challenges or existential distress undergo rigorous screening to eliminate those with a past history of psychosis.
Articles of Interest:
